Galectin Therapeutics, Inc. announced the election of Marc Rubin, M.D. as Chairman of the Board of Directors. Dr. Rubin, who has been serving as lead independent Director, succeeds James C. Czirr, who helped found the Company in 2000 and has served as Executive Chairman for the past seven years. Mr. Czirr will continue to serve as a Director.

Dr. Rubin is a leading bioscience industry executive with more than 25 years of senior management and Board experience in the development and commercialization of pharmaceuticals. Dr. Rubin is currently Executive Chairman of the Board of Directors of Titan Pharmaceuticals, Inc. and served as its President and Chief Executive Officer from October 2007 to January 2009. Dr. Rubin is a member of the Board of Directors of Curis Inc. and formerly served on the Board of Directors of Medarex, Inc., now a subsidiary of Bristol-Myers Squibb Company.

Dr. Rubin holds an M.D. from Cornell University Medical College and is board-certified in internal medicine with subspecialties in medical oncology and infectious diseases.